Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during

This section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire

Unprecedented Quarter Shows Company’s Strong Financial Position and Continued Momentum with its Multiple Sclerosis Clinical Trials and unbuzzdTM Recreational Beverage and Alcohol Metabolizer

TORONTO, Aug. 07, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“ Quantum BioPharma ” or the “ Company ”), is pleased to announce its financial and operational results for the second quarter ending June 30, 2025.

Overall, the Company is in a strong position having increased its current and total assets, compared to the previous quarter; eliminated th